US Patent Issued to Cambridge Enterprise on May 12 for "Treatment and prognosis of pancreatic cancer" (British Inventors)

ALEXANDRIA, Va., May 12 -- United States Patent no. 12,622,906, issued on May 12, was assigned to Cambridge Enterprise Ltd. (Cambridge, Great Britain).

"Treatment and prognosis of pancreatic cancer" was invented by Tony James Wu (Cambridge, Great Britain), Michael Gill (Cambridge, Great Britain), Martin Miller (Cambridge, Great Britain) and Oliver Cast (Cambridge, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides a CCR1 antagonist, or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of pancreatic cancer, in particular a CCR1 antagonist, for example in combination with one or more further therapeutic agents effective as anti-tumour agen...